COPENHAGEN, Denmark, Oct. 31, 2025 (GLOBE NEWSWIRE) -- BOOST Pharma, a clinical-stage cell biotech company focused on rare skeletal pediatric diseases, is proud to announce that new long-term data from the first-in-class BOOSTB4 stem cell therapy trial has been selected for presentation by BOOST Pharma co-founder Dr. Cecilia Götherström at the prestigious 15th International Conference on Osteogenesis Imperfecta (OI), taking place from October 29-31, 2025, in Hong Kong. The presentation will provide two-year ...